|
Colon Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
High lutein intake [odds ratio (OR), 0.63; 95% confidence interval (95% CI), 0.44-0.89], low refined grain intake (OR, 0.70; 95% CI, 0.53-0.94), or a high prudent diet score (OR, 0.66; 95% CI, 0.49-0.89) and PA/AA PPARgamma genotype were associated with reduced colon cancer risk.
|
15894676 |
2005 |
|
Colon Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Stratified meta-analysis indicated that PPAR-gamma 34 C>G was associated with colon cancer (OR = 0.8, 95% CI: 0.65-0.99, P = 0.04) in random-effect model, and the G allele decreased colon cancer risk.
|
20440859 |
2010 |
|
Colon Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The odd ratio for PPARgamma PA or AA genotype relative to the PP genotype for colon cancer was 0.9 (95% confidence interval, CI=0.8-1.0) and for rectal cancer was 1.2 (95% CI=1.0-1.5) adjusting for race, age, and sex.
|
15860437 |
2005 |
|
Colon Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
There was a significant interaction between the -200A>C IGFBP3 polymorphism and the Pro12Ala PPARgamma polymorphism and risk of colon cancer (p for interaction = 0.02) with individuals being at significantly lower risk if they had both the CC IGFBP3 genotype and the PA/AA PPARgamma genotype.
|
16489531 |
2006 |
|
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To investigate the relationship between PSF and PPARγ in colon cancer, we evaluated the effects of PSF expression in DLD-1 and HT-29 colon cancer cell lines, which express low and high levels of PPARγ, respectively PSF affected the ability of PPARγ to bind, and expression of PSF siRNA significantly suppressed the proliferation of colon cancer cells.
|
23516550 |
2013 |
|
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This finding suggests a potentially important use for PPARgamma ligands as chemopreventative agents in colon cancer.
|
12370429 |
2002 |
|
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Finally, EPA suppressed HT-29 cell growth and this effect was significantly reversed by the addition of GW, suggesting that in part the physiological actions of EPA are the result of PPARgamma activation.
|
18203887 |
2008 |
|
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To better understand their role, we studied the expression levels of all PPAR-isoforms and transcriptional partners such as the retinoid X receptor alpha (RXRalpha) and PPARgamma-coactivator-1 (PGC-1) by means of real-time PCR in 17 patients with colon cancer.
|
14670614 |
2004 |
|
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, SOX9, β-catenin and PPARγ expression levels are deregulated in the CRC tissue, and in colon cancer cell lines ligand-dependent PPARγ activation unevenly influences SOX9 and β-catenin expression and subcellular localization, suggesting a variable mechanistic role in colon carcinogenesis.
|
23583560 |
2013 |
|
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results indicate that the growth and differentiation of colon cancer cells can be modulated through PPARgamma.
|
9734398 |
1998 |
|
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To elucidate cdk5's role in PPARgamma ligand-induced antiproliferation of colon cancer cells, HT-29 cells were treated with ciglitazone.
|
16327995 |
2006 |
|
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We can therefore exclude this alteration as a mechanism of resistance to PPAR(gamma) ligands in patients with colon cancer.
|
15911106 |
2005 |
|
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that PPARgamma plays a role as a physiological regulator of colonic epithelial cell turnover and consequently predisposition to the development of colon cancer in early stage.
|
18391483 |
2008 |
|
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The molecules and signals that act to eradicate or initiate the apoptosis cascade in cancer cells, are elucidated, and these include caspases, Fas, Bax, Bid, APC, antisense hTERT, PUMA, 15-LOX-1, ceramide, butyrate, tributyrin and PPARgamma, whereas the molecules which promote colon cancer cell survival are p53 mutants, Bcl-2, Neu3 and COX-2.
|
15255176 |
2004 |
|
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated if the rexinoid 6-OH-11-O-hydroxyphenantrene (IIF) potentiates the antitumoral properties of PPARgamma ligands as ciglitazone and pioglitazone, on two colon cancer cell lines: HCA-7 and HCT-116.
|
20510503 |
2010 |
|
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
1,1-Bis(3'indolyl)-1-(p-substitutedphenyl)methanes containing p-trifluoromethyl (DIM-C-pPhCF)), p-t-butyl (DIM-C-pPhtBu), and p-phenyl (DIM-C-pPhC6H5) groups induce peroxisome proliferator-activated receptor gamma (PPARgamma)-mediated transactivation in HT-29, HCT-15, RKO, and SW480 colon cancer cell lines.
|
15342379 |
2004 |
|
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Expression of this protein may prevent PPARgamma ligand efficiency in colon cancer treatment.
|
17611675 |
2007 |
|
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interactions between PPAR Gamma and the Canonical Wnt/Beta-Catenin Pathway in Type 2 Diabetes and Colon Cancer.
|
28298922 |
2017 |
|
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, only retroviral transduction of the wild-type (WT), but not mutant, receptor could restore PPARgamma ligand-induced growth inhibition and differentiation in resistant colon cancer cell lines.
|
12591919 |
2003 |
|
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The role of peroxisome proliferator-activated receptor gamma in colon cancer and inflammatory bowel disease.
|
12946234 |
2003 |
|
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Involvement of peroxisome proliferator activated receptor gamma (PPARgamma) in the growth response of colon cancer cells has been suggested.
|
11950812 |
2002 |
|
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
1,1-Bis(3'-indolyl)-1-(p-substitutedphenyl)methanes are peroxisome proliferator-activated receptor gamma agonists but decrease HCT-116 colon cancer cell survival through receptor-independent activation of early growth response-1 and nonsteroidal anti-inflammatory drug-activated gene-1.
|
16155208 |
2005 |
|
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study suggested that a PPARgamma-Bcl-2 feedback loop may function to control the life-death continuum in colonic cells and that a deficiency in generation of PPARgamma ligands may precede the development of human colon cancer.
|
12269390 |
2002 |
|
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor gamma (PPARgamma), a member of the nuclear receptor superfamily, plays a role in adipocyte differentiation, type II diabetes, macrophage response to inflammation and is suggested to influence carcinogen-induced colon cancer.
|
15073042 |
2004 |
|
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chiral phenoxyacetic acid analogues inhibit colon cancer cell proliferation acting as PPARγ partial agonists.
|
30931956 |
2019 |